Characterization and comparison of the properties of sarcoma cell linesin vitroandin vivo
- 1 November 2009
- journal article
- Published by Springer Science and Business Media LLC in Human Cell
- Vol. 22 (4), 85-93
- https://doi.org/10.1111/j.1749-0774.2009.00073.x
Abstract
To expand the available tools for investigating human sarcomas, we characterized the primary properties of 22 common, uncommon, and newly characterized sarcoma cell lines representing eight different histological subtypes. Throughout the characterization process we noticed that in vitro markers and assays are poor indicators of tumorigenicity and that generated xenografts often bear little resemblance to the original histopathology. In vitro properties examined included morphology, proliferation rate, cell cycle characteristics, invasiveness, and immunohistochemical expression of p53 and phospho-AKT. In vivo properties examined included days to tumor formation in NOD/SCID mice, xenograft morphology in several locations and immunohistochemical expression of Ki67, p53 and phospho-AKT. We believe that such an in depth comparison of a large cohort of sarcoma cell lines will be useful in both designing and interpreting experiments aimed at elucidating both the molecular biology and efficacy of therapeutic agents in sarcomas. However, that data generated also suggests a small set of sarcoma cell lines may be inappropriate for generalizations regarding biological behavior of specific sarcoma subtypes. Integration of functional genomics or other more sophisticated assays of cell lines may help bridge the differences in vitro and in vivo.Keywords
This publication has 18 references indexed in Scilit:
- Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathwayJCI Insight, 2007
- Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and FutureThe Oncologist, 2007
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell linesInvestigational New Drugs, 2007
- Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53Journal of Cellular Biochemistry, 2006
- Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatinBritish Journal of Cancer, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaJournal of Clinical Oncology, 2004
- The Hallmarks of CancerCell, 2000
- Symbolic Description of Factorial Models for Analysis of VarianceJournal of the Royal Statistical Society Series C: Applied Statistics, 1973